 HOUSTON, Sept. 22, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center. The research, to be carried out by the laboratory of Johnathan Whetstine, PhD, the institutes director, will help identify new indications and potential biomarkers for Salarius lead drug candidate, seclidemstat. 